<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349193</url>
  </required_header>
  <id_info>
    <org_study_id>LAQ/5062</org_study_id>
    <secondary_id>2004-003943-28</secondary_id>
    <nct_id>NCT00349193</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod</brief_title>
  <official_title>A Multinational, Multicenter Randomized Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Efficacy, Tolerability and Safety of Two Doses of, Oral Laquinimod in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has
      immunomodulating properties. In a previous clinical study laquinimod showed evidence of
      biological activity by reducing the number of acute brain lesions.

      The duration of the current study is 36 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of brain lesions in the last 4 months of the study</measure>
    <time_frame>36 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Laquinimod 0.3 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laquinimod 0.3 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laquinimod 0.6 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laquinimod 0.6 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blinded Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>laquinimod 0.3</intervention_name>
    <description>laquinimod 0.3mg</description>
    <arm_group_label>Laquinimod 0.3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>laquinimod 0.6</intervention_name>
    <description>laquinimod 0.6mg</description>
    <arm_group_label>Laquinimod 0.6 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Blinded Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to give written informed consent

          2. Confirmed MS diagnosis as defined by the McDonald criteria

          3. R-R MS disease course.

          4. At least one gadolinium-enhanced lesion on screening MRI

          5. Women of child-bearing potential must practice a reliable method of birth control.

          6. Must understand the requirements of the study and agree to comply with the study
             protocol.

        Exclusion Criteria:

          1. Subjects who suffer from any form of progressive MS.

          2. Any condition which the investigator feels may interfere with participation in the
             study.

          3. Subjects with a clinically significant or unstable medical or surgical condition that
             would preclude safe and complete study participation,

          4. Subjects who received any investigational medication, immunosuppressives or cytotoxic
             agents within 6 months prior to screening

          5. Previous treatment with immunomodulators within two months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Giancarlo Comi</last_name>
    <role>Study Chair</role>
    <affiliation>Teva Pharmaceutical Industries, Ltd.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2006</study_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ekkehard Baader, MD</name_title>
    <organization>Teva Pharmaceutical Europe B.V.</organization>
  </responsible_party>
  <keyword>Relapsing Remitting Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

